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Abstract 
Review on IGFBP6, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: IBP6 
HGNC (Hugo): IGFBP6 
Location: 12q13.13 
DNA/RNA 
Description 
The size of the IGFBP6 gene is 4.91 kb and it 
contains 4 exons (Thierry-Mieg and Thierry-Mieg, 
2006). 
Transcription 
One 1175 bp transcript encodes the full-sized 240 
amino acid protein.  
Smaller transcripts sized 597, 705 and 463 bp may 
be incomplete and putatively encode fragments 
containing 51-140 amino acids (Thierry-Mieg and 
Thierry-Mieg, 2006). 
Protein 
Description 
IGFBP-6 belongs to the insulin-like growth factor 
binding protein family.  
It is expressed as a 240 amino acid proprotein, and 
processed to a 213-216 amino acid mature protein. 
 
Structure of the C-terminal domain of human IGFBP-6 
(Headey et al., 2004; Bach et al., 2013). 
 
It consists of 3 domains: the N- and C-terminal 
domains, which contain internal disulfide bonds, 
are joined by a linker domain. It contains 8 
disulfide bonds, 5 in the N-terminal IGFBP domain 
and 3 in the C-terminal domain (Neumann et al., 
1998; Neumann and Bach, 1999). Of these, the first 
3 N-terminal disulfides are unique, whereas the 
remaining 2 N-terminal and 3 C-terminal disulfides 
are homologous with other IGFBPs. A peptide 
based on the N-terminal subdomain is largely 
unstructured (Chandrashekaran et al., 2007), 
whereas the IGF binding subdomain is conserved 
with other IGFBPs. Human IGFBP-6 is O-
glycosylated on 5 Ser/Thr residues within the linker 
domain, which has a distinct sequence from other 
IGFBPs (Bach et al., 1992; Neumann et al., 1998). 
The C-terminal domain contains a thyroglobulin  
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type 1 fold (Headey et al., 2004), which is also true 
for other IGFBPs, and a functional nuclear 
localization sequence (Iosef et al., 2008). 
Expression 
IGFBP6 is widely expressed in human tissues, with 
low levels of transcripts found in most tissues. 
Expression is highest in smooth muscle, olfactory 
bulb, ganglia, retina and the atrioventricular node 
(Wu et al., 2013). IGFBP6 is also found in many 
body fluids, including serum, cerebrospinal fluid, 
amniotic fluid, and follicular fluid (Baxter and 
Saunders, 1992; Bach, 1999; Kolker et al., 2012). 
IGFBP6 expression is regulated in a cell-specific 
manner by cAMP, IGFs, retinoic acid, vitamin D, 
glucocorticoids, p53, beta-catenin, hedgehog, TGF-
beta and SEMA3B (Bach et al., 2013). 
Localisation 
Predominantly extracellular. Nuclear localization 
via a C-domain nuclear localization signal that 
binds importin-a has also been reported (Iosef et al., 
2008). 
Function 
Unlike other IGFBPs, IGFBP-6 has a ~50-fold 
binding preference for IGF-II over IGF-I. It 
therefore is a relatively specific inhibitor of IGF-II 
actions (Bach, 1999; Bach, 2005; Bach et al., 
2013). It is antiproliferative and proapoptotic in a 
number of cell lines in vitro (Bach, 1999; Bach, 
2005; Bach et al., 2013). At least some of its 
actions in regulating cell fate are mediated by 
interaction with Ku80, a DNA-end binding protein 
(Iosef et al., 2010). IGFBP-6 has also been reported 
to have IGF-independent actions, such as 
promotion of cancer cell migration an IGF-
independent mechanism that involves binding 
prohibitin-2 (Fu et al., 2007; Fu et al., 2013) and 
angiogenesis (Zhang et al., 2012). It has been 
reported to be a tumor suppressor in 
nasopharyngeal cancer through regulation of EGR-
1 expression (Kuo et al., 2010). 
As well as binding IGFs with high affinity, IGFBP-
6 also binds other unrelated proteins, including 
importin-α, prohibitin-2 and Ku80 as described 
above. Other proteins that bind IGFBP-6 inhibits 
osteoblast differentiation, which may be mediated 
by binding to LIM mineralization protein-1 (LMP-
1) (Strohbach et al., 2008), the vitamin D receptor 
(Cui et al., 2011), and the thyroid hormone-α 
receptor (Qiu et al., 2012). 
Global deletion of IGFBP6 expression does not 
result in a major phenotype, presumable because of 
functional redundancy with other IGFBPs. 
Homology 
IGFBP-6 shares homology with IGFBPs 1-5 in its 
N-terminal IGF binding domain and its C-terminal 
domain. It shares homology in its C-domain with 
other proteins containing a thyroglobulin type 1 
fold. 
IGFBP-6 is found in mammalian species including 
man, cow, rat and mouse, as well as trout and 
salmon. The IGFBP6 gene is duplicated in 
zebrafish, and each gene has a distinct expression 
pattern; however, overexpression of either gene 
inhibits embryonic growth and development (Wang 
et al., 2009). 
Implicated in 
Various cancers 
Note 
In many studies, IGFBP-6 expression is lower in 
(1) malignant vs normal cells; and (2) metastatic vs 
primary tumors, suggesting that it has an inhibitory 
effect on tumor development, at least in part by 
inhibiting IGF actions. Examples include 
rhabdomyosarcoma, head and neck cancer, lung 
cancer and gastric cancer (Bach et al., 2013). 
Exogenously added or overexpressed IGFBP-6 
inhibits rhabdomyosarcoma and neuroblastoma 
xenograft growth in mice (Grellier et al., 1998; 
Gallicchio et al., 2001). IGFBP6 has been 
implicated as a tumor suppressor in nasopharyngeal 
cancer by its role as a transcription factor for EGR-
1 (Kuo et al., 2010). 
Chronic renal failure 
Note 
Circulating IGFBP-6 levels are increased in patients 
with chronic renal failure (Powell et al., 1997; Van 
Doorn et al., 1999) and this, together with increased 
levels of other IGFBPs, may contribute to impaired 
IGF action in these patients. 
Proliferative vitreoretinopathy 
Note 
IGFBP-6 levels are increased in serum and vitreous 
from patients with this condition, and serum levels 
decreased after vitrectomy (Yu et al., 2014). 
Non islet-cell tumor hypoglycemia 
Note 
This rare condition is due to overexpression by 
tumors of a partially processed form of IGF-II that 
does not form normal serum complexes with 
IGFBPs and the acid-labile subunit and therefore 
has increased bioavailability. IGFBP-6 levels are 
increased in this condition (Van Doorn et al., 1999). 
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